A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.52 USD -1.95% Market Closed
Market Cap: 321m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Net Change in Cash
$53m
CAGR 3-Years
55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Change in Cash
$252m
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Net Change in Cash
$325m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
-20%
Pfizer Inc
NYSE:PFE
Net Change in Cash
-$1.6B
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Net Change in Cash
$6B
CAGR 3-Years
31%
CAGR 5-Years
169%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Change in Cash
$988.2m
CAGR 3-Years
72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aquestive Therapeutics Inc
Glance View

Market Cap
320.9m USD
Industry
Pharmaceuticals

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.06 USD
Overvaluation 42%
Intrinsic Value
Price
A

See Also

What is Aquestive Therapeutics Inc's Net Change in Cash?
Net Change in Cash
53m USD

Based on the financial report for Sep 30, 2024, Aquestive Therapeutics Inc's Net Change in Cash amounts to 53m USD.

What is Aquestive Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
55%

Over the last year, the Net Change in Cash growth was 745%. The average annual Net Change in Cash growth rates for Aquestive Therapeutics Inc have been 55% over the past three years .

Back to Top